Month: October 2015

  • MD Anderson, Biotech Form Antibody Discovery Company

    7 October 2015. MD Anderson Cancer Center in Houston is partnering with the biotechnology company Theraclone Sciences to form a new enterprise devoted to discovering antibodies for cancer therapies harnessing the immune system. The company named OncoResponse, also based in Houston, attracted $9.5 million in its first venture funding round. OncoResponse plans to adapt Theraclone’s…

  • Breakout Labs Adds Four Science-Based Start-Ups

    6 October 2015. Breakout Labs, an incubator of new enterprises based on discoveries from academic science labs, is adding four more companies to its portfolio. The new additions include companies developing advanced materials and sensors to measure food freshness, as well as discovering new therapies for diseases associated with the aging process. Breakout Labs is…

  • Partnership to Study Biomarkers in Liquid Biopsies

    6 October 2015. DeNovo Sciences, a developer of liquid biopsies and analytics, is teaming with bioTheranostics, a cancer diagnostics company using molecular biomarkers, to test the feasibility of combining their technologies. Financial and intellectual property details of the collaboration were not disclosed. In testing for solid tumor cancers, such as lung or breast cancer, doctors…

  • iPhone App Capturing Hepatitis C Research Data

    5 October 2015. An app made for the Apple iPhone now allows people with hepatitis C to record real-world data on their experiences with treatments and living with the disease. The C-Tracker app, developed by Boston Children’s Hospital, is available as a free download from the iPhone App Store. Hepatitis C is a viral infection affecting…

  • Influenza A Therapy Shown Working in Trial

    5 October 2015. A clinical trial testing a synthetic antibody designed to treat influenza A shows the treatment is effective in reducing the spread of flu viruses in humans. Visterra Inc., the therapy’s designer, also received a contract valued as much as $204.5 million from the U.S. Department of Health and Human Services to further…

  • Self-Propelled Particles Designed to Stop Bleeding

    2 October 2015. A biochemistry lab designed microscale particles that travel on their own through the body to stop heavy bleeding in trauma victims, surgery, and childbirth. Researchers at University of British Columbia in Vancouver, Canada led by biochemistry and engineering professor Christian Kastrup, published their findings in today’s issue of the journal Science Advances.…

  • Jet Fuel Additive Reduces Chance for Crash Explosions

    2 October 2015. Materials scientists and chemists designed a polymer additive that reduces the explosive nature of jet fuel in crashes or terror attacks, without compromising the fuel’s performance. Researchers from California Institute of Technology and Jet Propulsion Laboratory in Pasadena published their findings in today’s issue of the journal Science (paid subscription required). The…

  • RNA Therapy Biotech Earns $44 Million in IPO

    1 October 2015. A biotechnology company developing therapies based on RNA, genetic material that sends signals to cells, raised $43.75 million in its initial public stock offering. Mirna Therapeutics Inc. in Austin, Texas issued 6.25 million shares today at $7.00, and trades on the Nasdaq exchange under the symbol MIRN. Its shares closed today at…

  • Nanotech Cancer Center Gains $10.1M Funding

    1 October 2015. Cornell University and Memorial Sloan Kettering Cancer Center are developing cancer diagnostics and therapies with nanoscale particles, funded largely by a National Cancer Institute grant. NCI, part of National Institutes of Health, is providing $8.2 million to the institutions over five years, while Sloan Kettering is adding $1.9 million. Cornell and Sloan…